Free Trial

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$27.46 -1.00 (-3.50%)
As of 12:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$27.12
$29.00
50-Day Range
$23.74
$28.46
52-Week Range
$14.80
$40.47
Volume
281,968 shs
Average Volume
861,729 shs
Market Capitalization
$2.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.30
Consensus Rating
Buy

Company Overview

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 51% of companies evaluated by MarketBeat, and ranked 580th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -18.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -18.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CG Oncology has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    25.16% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 1.90%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.16% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 1.90%, indicating that investor sentiment is decreasing.
  • News Sentiment

    CG Oncology has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for CG Oncology this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of CG Oncology is held by insiders.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGON Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
CGON - CG Oncology Inc Trailing Returns - Morningstar
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the start of the year. Since then, CGON shares have decreased by 2.6% and is now trading at $27.9440.

CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The firm earned $0.05 million during the quarter, compared to analysts' expectations of $0.53 million. CG Oncology had a negative net margin of 15,945.17% and a negative trailing twelve-month return on equity of 16.71%.

CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

CG Oncology's top institutional shareholders include Wesbanco Bank Inc. (0.04%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
5/13/2025
Today
7/18/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
CIK
1991792
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$23.00
Potential Upside/Downside
+94.3%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.04 million
Net Margins
-15,945.17%
Pretax Margin
-15,945.17%
Return on Equity
-16.71%
Return on Assets
-16.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
30.97
Quick Ratio
30.97

Sales & Book Value

Annual Sales
$1.14 million
Price / Sales
1,902.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.63 per share
Price / Book
2.96

Miscellaneous

Outstanding Shares
76,220,000
Free Float
70,584,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
0.86
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners